<DOC>
	<DOCNO>NCT00751348</DOCNO>
	<brief_summary>This Phase 3b study conduct purpose registration GSK208136 vaccine Korea .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study GSK Biologicals ' Combined Measles-mumps-rubella-varicella Vaccine 208136</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include 11 24 month age , time vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Administration immunoglobulins and/or blood product six month enter study plan administration study period . Planned administration/ administration vaccine foreseen study protocol within 30 day prior 42 day study vaccine dose exception inactivate vaccine pneumococcal , Haemophilus influenzae type b conjugate vaccine , inactivate influenza , hepatitis A B vaccine diphtheria/tetanuscontaining vaccine administer eight day study vaccine dose . Previous vaccination measles , mumps , rubella and/or varicella . History measles , mumps , rubella and/or varicella/zoster disease . Known exposure measles , mumps , rubella and/or varicella within 30 day prior study start . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) , include systemic hypersensitivity neomycin . Major congenital defect serious chronic illness . Acute disease time enrolment . Rectal temperature ≥ 38°C axillary temperature ≥ 37.5°C time vaccination . Residence household high risk person e.g . : Newborn infant ( 04 week age ) Pregnant woman negative history chickenpox Persons known immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>second year life</keyword>
	<keyword>one-dose schedule</keyword>
	<keyword>varicella</keyword>
	<keyword>rubella</keyword>
	<keyword>measles</keyword>
	<keyword>mumps</keyword>
</DOC>